AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma.

Berra C, Leclair HM, Sebillot A, Schausi D, Guillo J, Baietti MF, Leucci E, Galibert MD, Corre S

Open source

DOI
10.1038/s41420-026-03057-3
Published
2026 Mar 23
Container
Cell death discovery
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41420-026-03057-3,
  title = {AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma.},
  author = {Berra C and Leclair HM and Sebillot A and Schausi D and Guillo J and Baietti MF and Leucci E and Galibert MD and Corre S},
  year = {2026},
  journal = {Cell death discovery},
  doi = {10.1038/s41420-026-03057-3},
  url = {https://doi.org/10.1038/s41420-026-03057-3}
}

RIS

TY  - JOUR
TI  - AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma.
AU  - Berra C
AU  - Leclair HM
AU  - Sebillot A
AU  - Schausi D
AU  - Guillo J
AU  - Baietti MF
AU  - Leucci E
AU  - Galibert MD
AU  - Corre S
PY  - 2026
JO  - Cell death discovery
DO  - 10.1038/s41420-026-03057-3
UR  - https://doi.org/10.1038/s41420-026-03057-3
ER  - 

APA

C, B., HM, L., A, S., D, S., J, G., MF, B., E, L., MD, G., & S, C. (2026). AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma.. Cell death discovery. https://doi.org/10.1038/s41420-026-03057-3

Source records